STSergey O. Tcherniuk

Sergey O. Tcherniuk

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sergey O. Tcherniuk has a total of 4 co-authors. Here are the top co-authors by number of shared publications:

  • Aldrian Gudrun

    Centre de Recherche de Biochimie Macromoléculaire, Centre National de la Recherche Scientifique (CNRS), Montpellier, France

    1 shared publication
  • Anatoly I. Potopalsky

    Institute of Molecular Biology and Genetics, National Academy of Sciences of Ukraine (NAN Ukraine), Kiev, Ukraine

    1 shared publication
  • Bastien Herman

    Institut de Biologie Structurale, Centre National de la Recherche Scientifique (CNRS), Grenoble, France

    1 shared publication
  • Jadwiga Chroboczek

    Institut de Biologie Structurale, Centre National de la Recherche Scientifique (CNRS), Grenoble, France

    1 shared publication

Latest Publications

  • Open Access

    Amitozyn Impairs Chromosome Segregation and Induces Apoptosis via Mitotic Checkpoint Activation

    by Bastien Herman, Aldrian Gudrun, Anatoly I. Potopalsky, Jadwiga Chroboczek, Sergey O. Tcherniuk

    Amitozyn (Am) is a semi-synthetic drug produced by the alkylation of major celandine (Chelidonium majus L.) alkaloids with the organophosphorous compound N,N’N’-triethylenethiophosphoramide (ThioTEPA). We show here that the treatment of living cells with Am reversibly perturbs the microtubule cytoskeleton, provoking a dose-dependent cell arrest in the M phase. Am changed the dynamics of tubulin polymerization in vitro, promoted the appearance of aberrant mitotic phenotypes in HeLa cells and induced apoptosis by the activation of caspase-9, caspase-3 and PARP, without inducing DNA breaks. Am treatment of HeLa cells induced changes in the phosphorylation of the growth suppressor pRb that coincided with maximum mitotic index. The dose-dependent and reversible anti-proliferative effect of Am was observed in several transformed cell lines. Importantly, the drug was also efficient against multidrug-resistant, paclitaxel-resistant or p53-deficient cells. Our results thus open the way to further pre-clinical evaluation of Am.